Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodríguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, González JD, Bolufer P, González M, Sanz MA; PETHEMA Group. Ortega JJ, et al. J Clin Oncol. 2005 Oct 20;23(30):7632-40. doi: 10.1200/JCO.2005.01.3359. J Clin Oncol. 2005. PMID: 16234524
Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial.
Ribera JM, Ortega JJ, Oriol A, Bastida P, Calvo C, Pérez-Hurtado JM, González-Valentín ME, Martín-Reina V, Molinés A, Ortega-Rivas F, Moreno MJ, Rivas C, Egurbide I, Heras I, Poderós C, Martínez-Revuelta E, Guinea JM, del Potro E, Deben G. Ribera JM, et al. Among authors: ortega jj, ortega rivas f. J Clin Oncol. 2007 Jan 1;25(1):16-24. doi: 10.1200/JCO.2006.06.8312. J Clin Oncol. 2007. PMID: 17194902 Clinical Trial.
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
Ribera JM, Oriol A, Sanz MA, Tormo M, Fernández-Abellán P, del Potro E, Abella E, Bueno J, Parody R, Bastida P, Grande C, Heras I, Bethencourt C, Feliu E, Ortega JJ. Ribera JM, et al. Among authors: ortega jj. J Clin Oncol. 2008 Apr 10;26(11):1843-9. doi: 10.1200/JCO.2007.13.7265. J Clin Oncol. 2008. PMID: 18398150 Clinical Trial.
High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.
Marco F, Bureo E, Ortega JJ, Badell I, Verdaguer A, Martínez A, Muñoz A, Madero L, Olivé T, Cubells J, Castel V, Sastre A, Maldonado MS, Díaz MA. Marco F, et al. Among authors: ortega jj. J Clin Oncol. 2000 Sep 15;18(18):3256-61. doi: 10.1200/JCO.2000.18.18.3256. J Clin Oncol. 2000. PMID: 10986058
Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF; PETHEMA Group, Spanish Society of Hematology. Ribera JM, et al. Among authors: ortega jj. Haematologica. 2002 Feb;87(2):154-66. Haematologica. 2002. PMID: 11836166 Clinical Trial.
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ; PETHEMA Group, Spain. Ribera JM, et al. Among authors: ortega jj. Haematologica. 2005 Oct;90(10):1346-56. Haematologica. 2005. PMID: 16219571 Clinical Trial.
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group. Oriol A, et al. Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145276 Free PMC article.
[Prevalence and prognostic significance of myeloid markers in adults with high-risk acute lymphoblastic leukemia].
Plensa E, Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández Ribas JM, Moreno MJ, del Potro E, Tormo M, Rivas C, Besalduch J, Sanz MA, Arias J, Fernández Calvo J, Moraleda JM, Bueno J, Feliu E, Ortega JJ; Grupo PETHEMA. Plensa E, et al. Among authors: ortega jj. Med Clin (Barc). 2005 Sep 3;125(7):241-6. doi: 10.1157/13078098. Med Clin (Barc). 2005. PMID: 16137483 Spanish.
Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J, Brunet S, Grañena A, Olivé T, Bueno J, Ribera JM, Petit J, Besses C, Llorente A, Guardia R, Macía J, Rovira M, Badell I, Vela E, Díaz de Heredia C, Vivancos P, Carreras E, Feliu E, Montserrat E, Julía A, Cubells J, Rozman C, Domingo A, Ortega JJ. Sierra J, et al. Among authors: ortega jj. J Clin Oncol. 1996 Apr;14(4):1353-63. doi: 10.1200/JCO.1996.14.4.1353. J Clin Oncol. 1996. PMID: 8648394 Clinical Trial.
130 results